Importance of Cellular Immunity and IFN-γ Concentration in Preventing SARS-CoV-2 Infection and Reinfection: A Cohort Study

Viruses. 2023 Mar 20;15(3):792. doi: 10.3390/v15030792.

Abstract

Recent studies have highlighted the underestimated importance of the cellular immune response after the emergence of variants of concern (VOCs) of SARS-CoV-2, and the significantly reduced neutralizing power of antibody titers in individuals with previous SARS-CoV-2 infection or vaccination. Our study included 303 participants who were tested at St. Catherine Specialty Hospital using the Quan-T-Cell SARS-CoV-2 in combination with the Quan-T-Cell ELISA (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) for the analysis of IFN-γ concentration, and with Anti-SARS-CoV-2 QuantiVac ELISA IgG (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) for the detection of human antibodies of the immunoglobulin class IgG against the S1 domain of the SARS-CoV-2 spike protein. The statistical analysis showed a significant difference in the concentration of IFN-γ between reinfected participants and those without infection (p = 0.012). Participants who were not infected or reinfected with SARS-CoV-2 after vaccination and/or previous SARS-CoV-2 infection had a significantly higher level of cellular immunity. Furthermore, in individuals without additional vaccination, those who experienced infection/reinfection had significantly lower levels of IFN-γ compared to uninfected participants (p = 0.016). Our findings suggest a long-lasting effect of cellular immunity, measured by IFN-γ concentrations, which plays a key role in preventing infections and reinfections after the emergence of SARS-CoV-2 variants of concern.

Keywords: COVID-19; Omicron variant; SARS-CoV-2; cellular immunity; humoral immunity; infection; vaccination.

MeSH terms

  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Cohort Studies
  • Humans
  • Immunity, Cellular
  • Immunoglobulin G
  • Interferon-gamma
  • Reinfection / prevention & control
  • SARS-CoV-2

Substances

  • spike protein, SARS-CoV-2
  • Antibodies, Viral
  • Immunoglobulin G
  • Interferon-gamma

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This research received no external funding.